Emend(aprepitant)
Aponvie, Aprepitant, Cinvanti, Emend (aprepitant) is a small molecule pharmaceutical. Aprepitant was first approved as Emend on 2003-03-26. It has been approved in Europe to treat neoplasms, postoperative nausea and vomiting, and vomiting. The pharmaceutical is active against substance-P receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| neoplasms | D009369 |
| signs and symptoms pathological conditions | D013568 |
Trade Name
FDA
EMA
Aponvie, Aprepitant, Cinvanti, Emend (discontinued: Emend)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Aprepitant
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| APONVIE | Heron Therapeutics | N-216457 RX | 2022-09-16 | 1 products, RLD, RS |
| CINVANTI | Heron Therapeutics | N-209296 RX | 2017-11-09 | 1 products, RLD, RS |
| EMEND | Merck & Co | N-021549 RX | 2003-03-26 | 2 products, RLD, RS |
| EMEND | Merck & Co | N-207865 RX | 2015-12-17 | 1 products, RLD, RS |
Show 1 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| aponvie | New Drug Application | 2024-03-13 |
| aprepitant | ANDA | 2024-09-09 |
| aprepitant aprepitant | ANDA | 2025-06-13 |
| cinvanti | New Drug Application | 2024-03-13 |
| emend | New Drug Application | 2024-07-05 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Aprepitant, Aponvie, Heron Theraps Inc | |||
| 9561229 | 2035-09-18 | DP | U-2161, U-3440 |
| 9808465 | 2035-09-18 | U-2161, U-3440 | |
| 9974742 | 2035-09-18 | DP | |
| 9974793 | 2035-09-18 | DP | |
| 9974794 | 2035-09-18 | DP | U-2161, U-3440 |
| 10500208 | 2035-09-18 | DP | |
| 10624850 | 2035-09-18 | U-2161, U-3440 | |
| 10953018 | 2035-09-18 | U-2161, U-3440 | |
| 11173118 | 2035-09-18 | DP | |
| Aprepitant, Emend, Merck | |||
| 8258132 | 2027-09-26 | DP | U-901, U-1743, U-1916 |
Clinical
Clinical Trials
215 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Vomiting | D014839 | — | R11.1 | 10 | 31 | 41 | 25 | 25 | 130 |
| Nausea | D009325 | — | R11.0 | 5 | 30 | 30 | 23 | 25 | 111 |
| Postoperative nausea and vomiting | D020250 | EFO_0004888 | — | 2 | 4 | 7 | 15 | 11 | 38 |
| Neoplasms | D009369 | — | C80 | 3 | 5 | 3 | 4 | 7 | 20 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 2 | 1 | 5 | 3 | 3 | 14 |
| Lymphoma | D008223 | — | C85.9 | 1 | 2 | — | 2 | 5 | 9 |
| Pruritus | D011537 | — | L29 | 1 | 3 | 1 | 1 | 1 | 7 |
| Leukemia | D007938 | — | C95 | — | 2 | — | 2 | 3 | 7 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | — | 1 | — | 1 | 4 | 6 |
| Healthy volunteers/patients | — | — | — | 4 | — | — | 1 | — | 5 |
Show 12 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Depression | D003863 | — | F33.9 | — | — | 9 | — | — | 9 |
| Major depressive disorder | D003865 | EFO_0003761 | F22 | — | — | 9 | — | — | 9 |
| Depressive disorder | D003866 | EFO_1002014 | F32.A | — | — | 9 | — | — | 9 |
| Multiple myeloma | D009101 | — | C90.0 | 1 | 1 | 1 | — | 4 | 7 |
| Myeloproliferative disorders | D009196 | — | D47.1 | — | — | 1 | — | 4 | 5 |
| Non-small-cell lung carcinoma | D002289 | — | — | 1 | 3 | 1 | — | 1 | 5 |
| Myeloid leukemia acute | D015470 | — | C92.0 | — | 2 | 1 | — | 1 | 4 |
| Lung neoplasms | D008175 | — | C34.90 | — | 2 | 1 | — | 1 | 4 |
| Carcinoma | D002277 | — | C80.0 | — | 2 | 1 | — | 1 | 4 |
| Plasma cell neoplasms | D054219 | — | — | — | — | 1 | — | 3 | 4 |
Show 12 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Non-hodgkin lymphoma | D008228 | — | C85.9 | 1 | 1 | — | — | 2 | 4 |
| Myelodysplastic syndromes | D009190 | — | D46 | — | 1 | — | — | 3 | 4 |
| Preleukemia | D011289 | — | — | — | 1 | — | — | 3 | 4 |
| Squamous cell carcinoma of head and neck | D000077195 | — | — | — | 3 | — | — | 1 | 4 |
| Alcoholism | D000437 | EFO_0003829 | F10.1 | — | 3 | — | — | — | 3 |
| Marijuana abuse | D002189 | EFO_0007191 | F12 | 1 | 2 | — | — | — | 3 |
| Ovarian epithelial carcinoma | D000077216 | — | — | — | 1 | — | — | 2 | 3 |
| Squamous cell carcinoma | D002294 | — | — | — | 2 | — | — | 1 | 3 |
| Head and neck neoplasms | D006258 | — | — | 1 | 1 | — | — | — | 2 |
| Hypertension | D006973 | EFO_0000537 | I10 | — | 1 | — | — | 1 | 2 |
Show 26 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hiv infections | D015658 | EFO_0000764 | B20 | 3 | — | — | — | — | 3 |
| Opioid-related disorders | D009293 | EFO_0005611 | F11 | 2 | — | — | — | — | 2 |
| Heroin dependence | D006556 | EFO_0004240 | — | 2 | — | — | — | — | 2 |
| Tobacco use disorder | D014029 | — | F17 | 1 | — | — | — | — | 1 |
| Substance-related disorders | D019966 | EFO_0003890 | F13 | 1 | — | — | — | — | 1 |
| Biological availability | D001682 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neuroblastoma | D009447 | EFO_0000621 | — | — | — | — | — | 3 | 3 |
| Plasmacytoma | D010954 | — | C90.3 | — | — | — | — | 3 | 3 |
| Chronic obstructive pulmonary disease | D029424 | EFO_0000341 | J44.9 | — | — | — | — | 2 | 2 |
| Obstructive lung diseases | D008173 | — | — | — | — | — | — | 2 | 2 |
| Myelodysplastic-myeloproliferative diseases | D054437 | — | — | — | — | — | — | 2 | 2 |
| Trophoblastic neoplasms | D014328 | — | — | — | — | — | — | 2 | 2 |
| Testicular neoplasms | D013736 | — | C62 | — | — | — | — | 2 | 2 |
| Cognitive dysfunction | D060825 | — | G31.84 | — | — | — | — | 1 | 1 |
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | — | — | — | — | 1 | 1 |
| Lung diseases | D008171 | EFO_0003818 | J98.4 | — | — | — | — | 1 | 1 |
Show 39 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Aprepitant |
| INN | aprepitant |
| Description | Aprepitant is a morpholine-based antiemetic, which is or the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective high-affinity antagonist of human substance P/neurokinin 1 (NK1) receptors. It has a role as an antidepressant, an antiemetic, a peripheral nervous system drug, a neurokinin-1 receptor antagonist and a substance P receptor antagonist. It is a member of triazoles, a member of morpholines, a cyclic acetal and a member of (trifluoromethyl)benzenes. |
| Classification | Small molecule |
| Drug class | tachykinin (neurokinin) receptor antagonists: NK1 receptor antagonists |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | C[C@@H](O[C@H]1OCCN(Cc2n[nH]c(=O)[nH]2)[C@H]1c1ccc(F)cc1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1 |
Identifiers
| PDB | — |
| CAS-ID | 170729-80-3 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1471 |
| ChEBI ID | 499361 |
| PubChem CID | 135413536 |
| DrugBank | DB00673 |
| UNII ID | 1NF15YR6UY (ChemIDplus, GSRS) |
Target
Agency Approved
TACR1
TACR1
Organism
Homo sapiens
Gene name
TACR1
Gene synonyms
NK1R, TAC1R
NCBI Gene ID
Protein name
substance-P receptor
Protein synonyms
neurokinin receptor 1, NK-1 receptor, NK-1R, Tachykinin receptor 1, tachykinin receptor 1 (substance P receptor; neurokinin-1 receptor)
Uniprot ID
Mouse ortholog
Tacr1 (21336)
substance-P receptor (Q8BYR7)
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Aponvie – Heron Therapeutics /de/
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Emend – Merck & Co
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Cinvanti – Heron Therapeutics /de/
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
Aprepitant
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 6,299 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
9,552 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use